TXG Earnings

TXG reported its earnings on 2026-02-12, showcasing a revenue of 166.03M against an estimate of 157.03M, resulting in a 5.73% surprise. The EPS was -0.13, surpassing the expected -0.19 by 31.58%. The stock experienced a 3.48% price change on the earnings day and a 9.59% change over the next five days, reflecting market reactions to the results.

Following TXG's earnings announcement on 2026-02-12, the stock price moved by 3.48% on the day of the release. Over the subsequent five days, it saw a 9.59% change. Historically, TXG's stock price tends to shift by an average of 5.61% in the 10 days leading up to earnings and 5.73% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate TXG's annual revenue to reach 139.41M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised upward by 23.69% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TXG's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised upward by 23.69%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TXG's stock price typically moves by 5.61% in the 10 days before its earnings and 5.73% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 139.41M.

The earnings call indicates strong financial health with a $482 million cash reserve and a focus on product innovation and market expansion. The Q&A reveals confidence in spatial consumables and biopharma revenue growth, despite CapEx headwinds. The strategic focus on AI and translational research, along with a strong balance sheet, supports positive sentiment. The market cap suggests moderate stock volatility, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.